Biosimilar

 

Humira

(Adalimumab)

Enbrel

(Etanercept)

Remicade

(Infliximab)

Rituxan

(Rituximab)

Avastin

(Bevacizumab)

Herceptin

(Trastuzumab)

Neulasta

(Pegfilgrastim)

Neupogen (Filgrastim)

Epogen (Epoetin alfa)

Amgen

Filed

(Jan 2017)

Phase III

(Oct 2016)

Phase III

(May 2016)

Filed

(Nov 2016)

Pfizer

Phase III

(Top-line results released in Jan 2017)

Will file in 1H17

Phase III

(Sep 2014)

Phase III

(Feb 2015)

Phase III

(Feb 2014)

Phase I

Sandoz

Will file in 1H17

Approved

(Aug 2016)

Will file in 2H17

Filed

(Nov 2015)

Approved*

(Jul 2017)

Approved

(Mar 2015)

Reviewing

Mylan/ Biocon

Phase III

(May 2015)

Phase I

Pre-clinical

Phase I

Filed

(Nov 2016)

Filed

(Feb 2017)

Phase I

Samsung Bioepis

Will file in 1H17

Will file in 1H17

Filed

(May 2016)

Phase III

(Mar 2015)

Will file in 1H17

Celltrion

Pre-clinical

Pre-clinical

Launched

(Dec 2016)

Will file in 1H17

Pre-clinical

Will file in 1H17

Coherus

Will file in 1H17

Filed

(Aug 2016)

Boehringer Ingelheim

Filed

(Jan 2017)

Will file in 4Q17

Eli Lilly

資料來源: 各公司網站、USFDA、Citi Research、筆者自行整理

喜歡這篇文章嗎?立即分享

你可能感興趣的文章